AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Döhner, Amir T. Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences